<u> </u>	gang Exhibition Center, Hall 2		Moderator
Time	Topic	Speaker	
08:00-08:15 08:15-08:20	The beauty of Taiwan	Ling-Min	-
J8:15-U8:2U		President of Taiwan Breast Cancer Soc Wen-Je Ko	
08:20-08:25	Opening Remarks	Mayor of Taipei	
00.25 00.20		Ta-Sen Yeh	
08:25-08:30		President of Taiwan S	
08:30-09:10	Plenary Lecture (1) Quantitative medicine for breast cancer patients	Charles Perou	Ling-Ming Tseng Chi-Cheng Huang
09:10-09:40	Immunotherapy for TNBC	Hope Rugo	Yen-Shen Lu Yi-Fang Tsai
09:40-10:10	CDK 4/6 inhibitors: Are the differences clinically	Dennis Slamon	Chiun-Sheng Huang
09.40-10.10	meaningful?		Lo Chiao
10:10-10:40	Coffee Breal	k	
TE	CS-GBCC Joint Session/Asian Expert Panel Discussion: Nation	nal and Regional Adaptat	ion Strategies
10:40-11:30	Issue about how to adapt the updated modern treatment for Asian patients-Part (I)	Byung Joo Chae Chiun-Sheng Huang Ching-Hung Lin Chun-Yu Liu Hiroji Iwata Jeong Eon Lee Wen-Ling Kuo Masakazu Toi Seho Park Soo Chin Lee Yoon-Sim Yap	Ling-Ming Tseng Yen-Shen Lu
11:30-12:20	Issue about how to adapt the updated modern treatment for Asian patients-Part (II)		
	Advances in Hormone Receptor Positive HER2 Negat	tive Advanced Breast Ca	ncer
12:20-13:00	Luncheon Symposium Considerations of the management of Asian postmenopausal women with ER+/HER2- advanced breast cancer	Wei-Pang Chung	Ming-Feng Hou Chin-Hua Tsai
13:00-13:30	Break		
13:30-14:00	The changing treatment landscape for premenopausal women with advanced breast cancer	Hsu-Huan Chou	Hong-Tai Chang Ta-Chung Chao
14:00-14:30	What tumor biology makes the difference in patients treated with CDK4/6 inhibitors?	Eva Ciruelos	Shin-Cheh Chen Ming-Yang Wang
14:30-15:00	Tyrosine kinase inhibitors for brain metastasis in HER2-positive breast cancer	Volkmar Müller	Kuan-Te Li Huan-Ming Hsu
15:00-15:30	Coffee Breal	k	
	Changing Treatment Landscape in Triple Neg	ative Breast Cancer	
15:30-16:00	Management of early breast cancer in patients with germline BRCA mutations	Karen Gelmon	Fang-Ming Chen Chih-Chiang Hung
16:00-16:30	Combination treatment strategy for TNBC-state of the art and the future	Rebecca Dent	Tsu-Yi Chao Dah-Cherng Yeh
16:30-17:10	Plenary Lecture (2) Non-industry sponsored clinical trials for breast cancer: past, present, and future	Michael Gnant	King-Jen Chang Kuo-Ting Lee
17:10-17:40	Trastuzumab biosimilars in oncology – data for ABP980	Hans-Christian Kolberg	Chia-Ming Hsieh

09:10-10:10 sponsored by Roche, Lilly 12:20-16:30 sponsored by Pfizer, Novartis, CANbridge, AstraZeneca, MSD

17:10-17:40 sponsored by Amgen

2021 Taipei International Breast Cancer Symposium 7F, Taipei Nangang Exhibition Center, Hall 2 Sun., October 31, 2021					
Time	Торіс	Speaker	Moderator		
Advances in Breast Imaging					
08:30-09:00	Applications on Al-enhanced breast imaging	Katja Pinker-Domenig	Tsen-Long Yang Jane Wang		
09:00-09:30	Multimodal response assessment to neoadjuvant treatment	Katja Pinker-Domenig	Wen-Hung Kuo Ming-Hsin Yeh		
New Horizons in HER2-Positive Breast Cancer					
09:30-10:00	Transforming clinical treatment in HER2 positive breast cancer with the new subcutaneous dosage	Sara M. Tolaney	Jyh-Cherng Yu Shih-Che Shen		
10:00-10:30	The progress of antibody drug conjugate treatment for HER2 positive breast cancer	Shanu Modi	Hsien-Kun Chang Yao-Lung Kuo		
10:30-11:00	Coffee Break				
Chemotherapy: Conventional Weapons, New Strategy					
11:00-11:25	Optimal choice of adjuvant chemotherapy regimen for EBC	Ming-Shen Dai	Shou-Tung Chen Chao-Ming Hung		
11:25-11:50	Strategies emerge for chemotherapy de-escalation in early breast cancer	Dwan-Ying Chang	Fiona Tsui-Fen Cheng Liang-Chih Liu		
11:50-12:30	Luncheon Symposium Outshined salvage therapy for advanced breast cancer	Kun-Ming Rau	Hwei-Chung Wang Chung-Chin Yao		
12:30-12:55	Potential predictive value of PIK3CA and ESR1 by liquid biopsy NGS for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC)	Wei-Wu Chen	Yao-Jen Chang Shih-Hsin Tu		
12:55-13:20	Break				
New Front of Local Regional Therapy for Early Breast Cancer					
13:20-13:45	Neomargin- surgical clip for tumor localization after Neoadjuvant chemotherapy	Chung-Liang Li	Frank Fu Ou-Yang Chin-Sheng Hung		
13:45-14:15	Knowledge gaps in oncoplastic surgery	Florian Fitzal	Dar-Ren Chen Hung-Wen Lai		
14:15-14:45	Pathological evaluation of axillary lymph nodes in breast cancer	Puay Hoon Tan	Shyr-Ming Sheen-Chen Cheng-Ping Yu		
14:45-15:15	Coffee Break				
15:15-15:40	Accelerated partial breast irradiation for early breast cancer: current status and future trends	Sung-Hsin Kuo	Jeng-Fong Chiou Shen-Liang Shih		
15:40-16:15	Radiologists' expectations for help from AI when reading mammograms	László Tabár	King-Jen Chang Hsiu-Hsi Chen		
16:15-17:15	After TIBCS 2021 What will you do for your patients tomorrow	Chieh-Han Chuang Chen-Hsiang Chang I-Chun Chen Jiun-I Lai Guo-Shiou Liao Yuan-Ching Chang Yen-Dun Tzeng	Fang-Ming Chen Ching-Hung Lin		
17:15-17:30	Award ceremony & closing		/ Fang-Ming Chen		

09:30-13:45 sponsored by Roche, Daiichi Sankyo, TTY, Sanofi, Eisai, ACTG, BD